Onno van de Stolpe, CEO, Galapagos

Onno van de Stolpe talks to Fintan Walton, about Galapagos' current business model and overall strategic outlook. They discuss the integration of BioFocus following its acquisition by Galapagos in November 2005, as well as the more recent acquisition of the drug discovery service division of Discovery Partners International. Onno talks in detail about managing Galapagos' strategic osteoarthritis alliance with GlaxoSmithKline and the challenges the company now faces as it expands its operations across the globe.

About Onno van de Stolpe

Onno van de Stolpe founded Galapagos in 1999 while he was Managing Director Genomics at IntroGene (now Crucell). Prior to joining IntroGene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the US. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Onno started his career as Manager Business Development at MOGEN in Leiden. He received an MSc degree from the Agricultural University in Wageningen.

About Galapagos

Galapagos NV (Euronext & LSE: GLPG), is an integrated drug discovery company accelerating toward entering the clinic in 2008 with its lead programme in rheumatoid arthritis. Since its IPO in May 2005, Galapagos has made several bold moves and executed a number of transforming deals; the first being the acquisition of BioFocus plc to form an integrated drug discovery service division in October 2005, followed by landing a broad drug discovery and development alliance in June 2006 with GlaxoSmithKline (GSK) in osteoarthritis, worth €137 million in upfront, milestone and equity payments and up to double digit royalties on commercial products. In July 2006 Galapagos acquired the drug discovery operations of Discovery Partners International for €4.3 million cash to form BioFocus DPI, a top tier global player in drug discovery. With several long term service agreements with Big Pharma, biotechnology, and patient foundation partners, downstream potential milestones for Galapagos now exceed €220 million. Galapagos currently employs more than 330 people, including 144 PhDs, and operates facilities in seven countries, with global headquarters in Mechelen, Belgium.

Galapagos is moving from strength to strength and has come to be recognized as a key player in the European biotechnology industry.
More information about Galapagos and BioFocus DPI can be found at www.glpg.com

Additional Resources:

(Available to current PharmaDeals subscribers only)

PharmaDeals Review Articles:
Galapagos Goes from Strength to Strength (July 2006)
Galapagos: An Evolving Company (November 2005)

PharmaDeals Agreements:

• GlaxoSmithKline and Galapagos Enter into Drug Discovery and Development Alliance in Osteoarthritis (Deal no. 24397)
• Galapagos Completes Acquisition of Drug Discovery Service Operations of Discovery Partners International (Deal no. 24485)
• Galapagos and OneWorld Health Collaborate to Develop New Drugs for the Treatment of Diarrhoeal Diseases (Deal no. 25177)
• Galapagos Enters into Collaboration with AstraZeneca (Deal no. 24932)
• Galapagos to Collaborate with Three R&D Institutes (Deal no. 24865)

For information about the PharmaDeals suite of intelligence products and how to subscribe, please use the following link: www.pharmaventures.com/pdeals.html